Prime Medicine PRME
NASDAQ PRME
$3.87 +0.06 (+1.44%)
As of: Oct 22, 2026 · 10:03 AM EDT

Prime Medicine (PRME) Change in Receivables (2024 - 2025)

Updated

Prime Medicine's Change in Receivables came in at -$120,000 for Q3 2025, compared with $55 million a year earlier.

Analysis

Prime Medicine (PRME) Change in Receivables (2024 - 2025) Analysis & Trends

Going back to Q3 2024, Prime Medicine's Change in Receivables data covers 4 quarters.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change Receivables (Qtr)
1 Eli Lilly 1,163.48 Bn 1,132.06 Bn 19.71 Bn -
2 Johnson & Johnson 631.16 Bn 549.69 Bn 17.26 Bn 1.35 Bn
3 AbbVie 502.63 Bn 475.74 Bn 12.70 Bn 1.37 Bn
4 Merck 378.53 Bn 332.91 Bn 12.21 Bn -
5 Novartis Ag 302.83 Bn 266.82 Bn 11.24 Bn -
6 Astrazeneca 265.92 Bn 239.60 Bn 12.86 Bn -
7 Amgen 240.87 Bn 196.27 Bn 7.24 Bn 1.09 Bn
8 Gilead Sciences 194.04 Bn 168.24 Bn 6.22 Bn 333.00 Mn
9 Pfizer 172.14 Bn 118.78 Bn 10.94 Bn -
10 Prime Medicine 684.97 Mn 63.44 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2025 -120,000.00
Jun 30, 2025 103,000.00
Mar 31, 2025 17,000.00
Sep 30, 2024 55.00 Mn
API Access

Prime Medicine Change in Receivables API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=change-in-receivables&ticker=PRME&period=max&api_key=YOUR_API_KEY